E-viri
Recenzirano
-
Lazarus, J.V.; Safreed-Harmon, K.; Stumo, S.R.; Jauffret-Roustide, M.; Maticic, M.; Reic, T.; Schatz, E.; Tallada, J.; Harris, M.
The International journal of drug policy, 09/2017, Letnik: 47, Številka: Suppl. CJournal Article
In 2016, the World Health Organization (WHO) called for the elimination of viral hepatitis as a public health threat and established the ambitious targets of achieving an 80% reduction in new infections and a 65% reduction in deaths from hepatitis C virus (HCV) by 2030. The sharing of unsterile injecting equipment is a major driver of the European region's HCV epidemic, and European countries are unlikely to reach the WHO targets unless they squarely address the HCV prevention, testing and treatment needs of people who inject drugs. Here, Lazarus et al discuss the European Liver Patients' Association's Hep-CORE study to provide insight into how national governments are responding to viral hepatitis.
